Payment overview · 2025
General Payments
$205.66
11 reported records · 7 companies
Healthcare provider profile · identity verified
Gregory S Byrd, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · WOODSTOCK, VA · NPI 1396744488
Verified facts
What the public records show
CMS Open Payments records show Gregory S Byrd, M.D. received $205.66 in general payments during 2025 across 11 reported records.
PFIZER INC. accounted for 38.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 347 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 347 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 245 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $79.67 | 38.7% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $34.68 | 16.9% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $22.84 | 11.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.03 | 9.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.66 | 8.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.00 | 8.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $13.78 | 6.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $205.66 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $62.99 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $41.72 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $34.68 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $22.84 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $22.84 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $22.84 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $21.27 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $20.03 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $17.66 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $17.00 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $16.68 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $16.68 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $16.68 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.35 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $13.78 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $13.78 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 245 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 347 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 113 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 122 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
347 | 62 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
347 | 62 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
113 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
122 | 23 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
245 | 45 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 608 | 168 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 507 | 156 |
| Amlodipine Besylate | Amlodipine Besylate | 486 | 139 |
| Lisinopril | Lisinopril | 450 | 131 |
| Levothyroxine Sodium | Levothyroxine Sodium | 391 | 88 |
| Jardiance | Empagliflozin | 347 | 62 |
| Metformin Hcl | Metformin Hcl | 295 | 74 |
| Metoprolol Succinate | Metoprolol Succinate | 250 | 71 |
| Eliquis | Apixaban | 245 | 45 |
| Omeprazole | Omeprazole | 237 | 62 |
| Furosemide | Furosemide | 230 | 72 |
| Losartan Potassium | Losartan Potassium | 204 | 57 |
| Tamsulosin Hcl | Tamsulosin Hcl | 194 | 56 |
| Gabapentin | Gabapentin | 190 | 47 |
| Pantoprazole Sodium | Pantoprazole Sodium | 189 | 58 |
| Metoprolol Tartrate | Metoprolol Tartrate | 175 | 45 |
| Simvastatin | Simvastatin | 171 | 48 |
| Alendronate Sodium | Alendronate Sodium | 166 | 45 |
| Lorazepam | Lorazepam | 160 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 153 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 153 | 45 |
| Potassium Chloride | Potassium Chloride | 146 | 36 |
| Montelukast Sodium | Montelukast Sodium | 139 | 36 |
| Sertraline Hcl | Sertraline Hcl | 136 | 24 |
| Tramadol Hcl | Tramadol Hcl | 133 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 123 | 32 |
| Ozempic | Semaglutide | 122 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 116 | 28 |
| Mounjaro | Tirzepatide | 113 | 20 |
| Meloxicam | Meloxicam | 112 | 38 |
| Carvedilol | Carvedilol | 110 | 27 |
| Buspirone Hcl | Buspirone Hcl | 109 | 21 |
| Mirtazapine | Mirtazapine | 104 | 19 |
| Famotidine | Famotidine | 100 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 94 | 33 |
| Pioglitazone Hcl | Pioglitazone Hcl | 93 | 25 |
| Quetiapine Fumarate | Quetiapine Fumarate | 92 | 11 |
| Pregabalin | Pregabalin | 90 | 16 |
| Alprazolam | Alprazolam | 89 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 89 | 28 |
| Clonidine Hcl | Clonidine Hcl | 86 | 17 |
| Spironolactone | Spironolactone | 85 | 25 |
| Trazodone Hcl | Trazodone Hcl | 83 | 20 |
| Ondansetron Odt | Ondansetron | 75 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 73 | 20 |
| Chlorthalidone | Chlorthalidone | 72 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 72 | 28 |
| Donepezil Hcl | Donepezil Hcl | 71 | 13 |
| Ezetimibe | Ezetimibe | 71 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 70 | 27 |
| Atenolol | Atenolol | 68 | 20 |
| Clonazepam | Clonazepam | 68 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 67 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 66 | 17 |
| Allopurinol | Allopurinol | 65 | 21 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 65 | 18 |
| Glimepiride | Glimepiride | 64 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 60 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 60 | 20 |
| Prednisone | Prednisone | 60 | 34 |
| Ipratropium Bromide | Ipratropium Bromide | 58 | 19 |
| Celecoxib | Celecoxib | 56 | 15 |
| Memantine Hcl | Memantine Hcl | 56 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 56 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 53 | suppressed |
| Bumetanide | Bumetanide | 51 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 50 | 12 |
| Warfarin Sodium | Warfarin Sodium | 50 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 47 | 18 |
| Irbesartan | Irbesartan | 45 | 14 |
| Januvia | Sitagliptin Phosphate | 45 | suppressed |
| Myrbetriq | Mirabegron | 41 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 40 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 40 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 40 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 40 | 12 |
| Midodrine Hcl | Midodrine Hcl | 40 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 39 | suppressed |
| Synthroid | Levothyroxine Sodium | 39 | 12 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 38 | suppressed |
| Cephalexin | Cephalexin | 37 | 30 |
| Xarelto | Rivaroxaban | 37 | suppressed |
| Temazepam | Temazepam | 36 | suppressed |
| Finasteride | Finasteride | 33 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 33 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 32 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 32 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | 11 |
| Baclofen | Baclofen | 31 | suppressed |
| Entresto | Sacubitril/Valsartan | 31 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 31 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | 11 |
| Propranolol Hcl Er | Propranolol Hcl | 29 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 29 | suppressed |
| Clonidine | Clonidine | 28 | suppressed |
| Nystatin | Nystatin | 27 | 13 |
| Terazosin Hcl | Terazosin Hcl | 27 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 25 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 24 | suppressed |
| Ibuprofen | Ibuprofen | 24 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 23 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 23 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 13 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Lidocaine | Lidocaine | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Dupixent Syringe | Dupilumab | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 14 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | 11 |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Triazolam | Triazolam | 14 | suppressed |
| Acetazolamide | Acetazolamide | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Donepezil Hcl Odt | Donepezil Hcl | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Rivastigmine | Rivastigmine | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Unifine Pentips Plus | Pen Needle, Diabetic | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 12 | suppressed |
| Klor-Con M10 | Potassium Chloride | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Mesalamine Dr | Mesalamine | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Famciclovir | Famciclovir | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $205.66 · 11 records | PFIZER INC. | ABRYSVO, CAPVAXIVE, COMIRNATY, ELIQUIS, GARDASIL 9, JARDIANCE, MOUNJARO, NURTEC ODT, Ozempic, PREVNAR 20, Rybelsus, SHINGRIX, The Cologuard Plus Collection Kit, VAXNEUVANCE, ZAVZPRET, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error